BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

...Inc. (NYSE:TMO) is marketing a real-time PCR kit for the detection of RNA from 2019-nCoV. GenapSys Inc....
...in a series C round (see “GenapSys Rolls Out a Smaller, Cheaper Sequencer” ). The GenapSys...
...2019n-CoV content is free to all who visit the site. Steve Usdin, Washington Editor Thermo Fisher Scientific Inc. GenapSys Inc. CDC U.S...
BioCentury | Nov 20, 2019
Finance

With Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer

...designed to deliver high-accuracy results at low cost without the need for a central laboratory. GenapSys Inc.'s...
...GenapSys founder and CEO Hesaam Esfandyarpour told BioCentury. "Over time, low-cost, high-quality sequencing options like GenapSys'...
...million series B. GenapSys has raised $166 million to date. Over the past six years, GenapSys...
BioCentury | Nov 18, 2013
Financial News

GenapSys completes venture financing

GenapSys Inc. , Redwood City, Calif. Business: Genomics Date completed: 11/14/13 Type: Venture financing Raised: $37 million Investors: Decheng Capital; IPV Capital; Stanford StartX Fund; private investors; institutional investors WIR Staff...
BioCentury | Nov 15, 2013
Financial News

GenapSys raises $37M in series B

...Capital and IPV Capital. New investors Stanford StartX and private and institutional investors also participated. GenapSys'...
...110 system is a next-generation DNA sequencing system that integrates advanced fluidics and analytical capabilities. GenapSys...
Items per page:
1 - 4 of 4
BioCentury | Feb 6, 2020
Product Development

2019-nCoV diagnostics ramp up in China, globally

...Inc. (NYSE:TMO) is marketing a real-time PCR kit for the detection of RNA from 2019-nCoV. GenapSys Inc....
...in a series C round (see “GenapSys Rolls Out a Smaller, Cheaper Sequencer” ). The GenapSys...
...2019n-CoV content is free to all who visit the site. Steve Usdin, Washington Editor Thermo Fisher Scientific Inc. GenapSys Inc. CDC U.S...
BioCentury | Nov 20, 2019
Finance

With Foresite backing $90M round, GenapSys rolls out a smaller, cheaper sequencer

...designed to deliver high-accuracy results at low cost without the need for a central laboratory. GenapSys Inc.'s...
...GenapSys founder and CEO Hesaam Esfandyarpour told BioCentury. "Over time, low-cost, high-quality sequencing options like GenapSys'...
...million series B. GenapSys has raised $166 million to date. Over the past six years, GenapSys...
BioCentury | Nov 18, 2013
Financial News

GenapSys completes venture financing

GenapSys Inc. , Redwood City, Calif. Business: Genomics Date completed: 11/14/13 Type: Venture financing Raised: $37 million Investors: Decheng Capital; IPV Capital; Stanford StartX Fund; private investors; institutional investors WIR Staff...
BioCentury | Nov 15, 2013
Financial News

GenapSys raises $37M in series B

...Capital and IPV Capital. New investors Stanford StartX and private and institutional investors also participated. GenapSys'...
...110 system is a next-generation DNA sequencing system that integrates advanced fluidics and analytical capabilities. GenapSys...
Items per page:
1 - 4 of 4